SCHEMBL5135915

SCHEMBL5135915

CCCCN(Cc1cccc(OC)c1OC)Cc1c(-c2ccc(OC)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCHE P06276 11/20 0.41
C5AR1 P21730 1/20 0.39
CASR P41180 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX2 P34913 1/20 0.38
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ATP4A P20648 1/20 0.37
ATP4B P51164 1/20 0.37
GNRHR P30968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137330 0.96 BCHE (0.43) BCHEC5AR1CASRMEN1KMT2A
SCHEMBL5137007 0.93 DRD2 (0.38) BCHEC5AR1CASRDRD2DRD3
SCHEMBL5137401 0.92 CASR (0.41) BCHEC5AR1CASRMEN1KMT2A
SCHEMBL5137301 0.92 BCHE (0.45) BCHEC5AR1CASRMEN1KMT2A
SCHEMBL5136313 0.92 BCHE (0.43) BCHEC5AR1CASRMEN1KMT2A
SCHEMBL5136445 0.91 DRD2 (0.38) BCHEC5AR1CASRDRD2DRD3
SCHEMBL5069962 0.88 BCHE (0.45) BCHEC5AR1CASRTSHR
SCHEMBL5137647 0.88 CASR (0.37) BCHEC5AR1CASRDRD2DRD3
SCHEMBL5136715 0.88 C5AR1 (0.43) BCHEC5AR1CASRMEN1KMT2A
SCHEMBL5165790 0.87 GNRHR (0.46) C5AR1DRD2DRD3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed